135 related articles for article (PubMed ID: 20531295)
1. Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells.
Lee SH; Shen GN; Jung YS; Lee SJ; Chung JY; Kim HS; Xu Y; Choi Y; Lee JW; Ha NC; Song GY; Park BJ
Oncogene; 2010 Aug; 29(32):4576-87. PubMed ID: 20531295
[TBL] [Abstract][Full Text] [Related]
2. Blocking of p53-Snail binding, promoted by oncogenic K-Ras, recovers p53 expression and function.
Lee SH; Lee SJ; Jung YS; Xu Y; Kang HS; Ha NC; Park BJ
Neoplasia; 2009 Jan; 11(1):22-31, 6p following 31. PubMed ID: 19107228
[TBL] [Abstract][Full Text] [Related]
3. p53 activation by blocking Snail: a novel pharmacological strategy for cancer.
Lee SH; Park BJ
Curr Pharm Des; 2011; 17(6):610-7. PubMed ID: 21391911
[TBL] [Abstract][Full Text] [Related]
4. p53, secreted by K-Ras-Snail pathway, is endocytosed by K-Ras-mutated cells; implication of target-specific drug delivery and early diagnostic marker.
Lee SH; Lee SJ; Chung JY; Jung YS; Choi SY; Hwang SH; Choi D; Ha NC; Park BJ
Oncogene; 2009 May; 28(19):2005-14. PubMed ID: 19347028
[TBL] [Abstract][Full Text] [Related]
5. Extracellular p53 fragment re-enters K-Ras mutated cells through the caveolin-1 dependent early endosomal system.
Lee SH; Woo TG; Lee SJ; Kim JS; Ha NC; Park BJ
Oncotarget; 2013 Dec; 4(12):2523-31. PubMed ID: 24344114
[TBL] [Abstract][Full Text] [Related]
6. Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer.
Hammoudeh SM; Venkatachalam T; Ansari AW; Bendardaf R; Hamid Q; Rahmani M; Hamoudi R
Front Immunol; 2020; 11():569671. PubMed ID: 33381110
[TBL] [Abstract][Full Text] [Related]
7. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.
Hiraki M; Hwang SY; Cao S; Ramadhar TR; Byun S; Yoon KW; Lee JH; Chu K; Gurkar AU; Kolev V; Zhang J; Namba T; Murphy ME; Newman DJ; Mandinova A; Clardy J; Lee SW
Chem Biol; 2015 Sep; 22(9):1206-16. PubMed ID: 26320861
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
9. NF2 blocks Snail-mediated p53 suppression in mesothelioma.
Cho JH; Lee SJ; Oh AY; Yoon MH; Woo TG; Park BJ
Oncotarget; 2015 Apr; 6(12):10073-85. PubMed ID: 25823924
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a chemical inhibitor against K-Ras-induced p53 suppression through natural compound screening.
Lee SJ; Jung YS; Lee SH; Chung HY; Park BJ
Int J Oncol; 2009 Jun; 34(6):1637-43. PubMed ID: 19424582
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.
Wang W; Kim SH; El-Deiry WS
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11003-8. PubMed ID: 16835297
[TBL] [Abstract][Full Text] [Related]
13. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
14. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (CD-1) male mice exposed transplacentally to AZT.
Hong HH; Dunnick J; Herbert R; Devereux TR; Kim Y; Sills RC
Environ Mol Mutagen; 2007; 48(3-4):299-306. PubMed ID: 16395694
[TBL] [Abstract][Full Text] [Related]
16. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
[TBL] [Abstract][Full Text] [Related]
17. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
Wiman KG
Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
[TBL] [Abstract][Full Text] [Related]
18. Loss of p53 cooperates with K-ras activation to induce glioma formation in a region-independent manner.
Muñoz DM; Tung T; Agnihotri S; Singh S; Guha A; Zadeh G; Hawkins C
Glia; 2013 Nov; 61(11):1862-72. PubMed ID: 24038521
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers.
Kitagawa Y; Wong F; Lo P; Elliott M; Verburgt LM; Hogg JC; Daya M
Am J Respir Cell Mol Biol; 1996 Jul; 15(1):45-54. PubMed ID: 8679221
[TBL] [Abstract][Full Text] [Related]
20. A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice.
Wang Y; Zhang Z; Lubet RA; You M
Oncogene; 2006 Feb; 25(8):1277-80. PubMed ID: 16247444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
